Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 12/20 | 0.64 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD5 | P21918 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10614957 | 0.86 | DRD3 (0.52) | DRD3DRD2HTR1ADRD1DRD4 | |
| SCHEMBL2295365 | 0.83 | DRD3 (0.47) | DRD3HTR1ACHRM2HTR2B | |
| SCHEMBL2296807 | 0.83 | DRD3 (0.47) | DRD3HTR1ACHRM2HTR2B | |
| SCHEMBL9640630 | 0.83 | DRD3 (0.44) | DRD3HTR1ACHRM2HTR2B | |
| Hydrochloric Acid SCHEMBL9640898 | 0.82 | DRD3 (0.43) | DRD3HTR1ACHRM2HTR2B | |
| SCHEMBL9641992 | 0.82 | CNR2 (0.45) | DRD3HTR1ACHRM2HTR2B | |
| SCHEMBL13093625 | 0.82 | CNR2 (0.45) | DRD3HTR1ACHRM2HTR2B | |
| SCHEMBL12363949 | 0.82 | CNR2 (0.45) | DRD3HTR1ACHRM2HTR2B | |
| SCHEMBL11164952 | 0.81 | DRD3 (0.69) | DRD3DRD2HTR1ADRD1DRD4 | |
| SCHEMBL9641532 | 0.81 | DRD3 (0.67) | DRD3DRD2HTR1ACHRM2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642855-B2 | Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642855-B2 | Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | PFIZER INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-9156845-B2 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2015-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | LRRK2, PARK7, BRCA1 | DRD3 595/4885DRD2 341/4885HTR1A 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.